本研究在没有表皮生长因子受体 (EGFR) 突变的非小细胞肺癌 (NSCLC) 患者中调查了 CD151（一种与癌症进展相关的蛋白质）。这些患者的治疗选择往往有限。该研究采用回顾性分析检查了癌症基因组图谱中的 157 份腺癌活检标本和 199 例患者病例，将 CD151 表达与患者生存相关联。细胞研究表明，CD151 与 EGFR 相互作用，影响表皮生长因子 (EGF) 诱导的细胞增殖以及 EGFR 抑制剂厄洛替尼的有效性。 CD151 表达与 EGFR 突变状态之间存在很强的相关性。在没有 EGFR 突变的情况下，高 CD151 表达与较差的生存结果相关。生物学检测表明，CD151 与 EGFR 共定位并关联，通过 AKT 和 ERK1/2 途径在调节 EGF 诱导的细胞增殖中发挥关键作用。重要的是，CD151 表达被发现会影响 EGFR 酪氨酸激酶抑制剂厄洛替尼的抗增殖作用。在没有 EGFR 突变的情况下，高 CD151 表达与较差的生存结果相关。它可以作为潜在的预后标志物并影响细胞对 EGFR 靶向治疗的反应。这项研究强调 CD151 作为 NSCLC 治疗干预的潜在新靶点，特别是在缺乏 EGFR 突变的人群中。© 2024 作者。北京干细胞与再生医学研究院和John Wiley联合出版的《细胞增殖》

This study investigates CD151, a protein linked to cancer progression, in non-small cell lung cancer (NSCLC) patients without epidermal growth factor receptor (EGFR) mutations. These patients often have limited treatment options. The study used retrospective analysis to examine 157 adenocarcinoma biopsy specimens and 199 patient cases from The Cancer Genome Atlas, correlating CD151 expression with patient survival. Cellular studies revealed that CD151 interacts with EGFR, influencing epidermal growth factor (EGF)-induced cell proliferation and the effectiveness of the EGFR inhibitor, erlotinib. A strong association was found between CD151 expression and EGFR mutation status. High CD151 expression in the absence of EGFR mutations is correlated with poorer survival outcomes. Biological assays showed that CD151 colocalizes and associates with EGFR, playing a crucial role in regulating EGF-induced cell proliferation via the AKT and ERK1/2 pathways. Importantly, CD151 expression was found to influence the anti-proliferative effects of the EGFR tyrosine kinase inhibitor, erlotinib. High CD151 expression, in the absence of EGFR mutations, was associated with poorer survival outcomes. It could serve as a potential prognostic marker and influence cellular responses to EGFR-targeted treatments. This study highlights CD151 as a potential novel target for therapeutic intervention in NSCLC, especially in populations lacking EGFR mutations.© 2024 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.